心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay)
ANH; ANF; CDD; Atrial Natriuretic Factor; Atrial Natriuretic Hormone; Atriopeptin; Cardionatrine; Cardiodilatin
（注：單次混測多因子不超過8個指標 ）
- 編號LMA225Si
- 物種Rhesus monkey (Simian，恒河猴) 相同的名稱，不同的物種。
- 實驗方法競爭抑制
- 反應(yīng)時長1.5h
- 檢測范圍0.98-1000pg/mL
- 靈敏度最小可檢測劑量小于等于0.327 pg/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標數(shù) 7指標數(shù) 6指標數(shù) 5指標數(shù) 4指標數(shù) 3指標數(shù) 2指標數(shù)1指標數(shù)
- 價格 ¥ 3033 ¥ 3149 ¥ 3324 ¥ 3558 ¥ 3791 ¥ 4141 ¥ 4666 ¥ 5832 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
特異性
本試劑盒用于檢測心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 78-98 | 83 |
| EDTA plasma(n=5) | 96-104 | 101 |
| heparin plasma(n=5) | 84-98 | 95 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-98% | 82-90% | 86-102% | 91-101% |
| EDTA plasma(n=5) | 86-102% | 82-92% | 98-105% | 78-102% |
| heparin plasma(n=5) | 88-97% | 93-101% | 81-88% | 86-93% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備；
2. 加樣（標準品、樣本、磁珠、檢測溶液A）標準品或樣本50μL及磁珠10μL，加檢測溶液A50μL，
37°C酶標板振蕩器孵育60分鐘；
3. 磁吸洗板3次；
4. 加檢測溶液B100μL，37°C振動孵育30分鐘；
5. 磁吸洗板3次；
6. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標準品或標本以及磁珠、標記VEGFA，標記的心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)和未標記的心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體競爭結(jié)合，然后將未結(jié)合物洗凈后，加入PE標記的親和素，再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法)呈負相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Rhesus monkey (Simian，恒河猴) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| CEA225Si | 心鈉肽(ANP)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA225Si | 心鈉肽(ANP)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| 8 | Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular Function [PubMed: 21616283] |
| Basic Research in Cardiology | Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgery [PubMed: 21769675] |
| Neuropsychobiology. | Atrial natriuretic Peptide, arginine vasopressin Peptide and cortisol serum levels in opiate-dependent patients [PubMed: 23406607] |
| European addiction research | Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment. [Pubmed: 24356727] |
| Crit Care. | Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyx [Pubmed:25497357] |
| Diabet Med.? | Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes. [Pubmed:26927445] |
| J Ethnopharmacol | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by reCavia (Guinea pig )lating p38 and NF-κb pathway [Pubmed:26970569] |
| Journal of Babylon University/Pure and Applied Sciences | Blood Pressure and Atrial Natriuretic Peptide (ANP) Levels in Patients with Autosomal Dominant Polycystic Kidney Disease. [papers:uobj_paper_2016_62613672.pdf] |
| PLoS One | Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathy [pubmed:29240788] |
| Drug Delivery | Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy. [pubmed:29063791] |
| Elife | SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylation [Pubmed:29504933] |
| Science?of the?Total?Environment | Co-exposure of silica nanoparticles and methylmercury induced cardiac toxicity and [Pubmed:29727991] |
| The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice [Pubmed:29929978] |
| Pediatric Cardiology | Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart Disease [Pubmed:29392348] |
| FASEB?Journal | Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure [Pubmed: 30230922] |
| Endokrynologia Polska | Endothelin-1 (ET-1), N-terminal fragment of proatrial natriuretic peptide (NTpro-ANP) and tumor necrosis factor alpha (TNF-α) in children with primary hypertension?… [Pubmed: 30359461] |
| International Journal of Peptide Research and Therapeutics | ANP/NPRA Inhibits Epithelial-Mesenchymal Transition of Airway by Targeting Smad3 in Asthma [] |
| Van Veterinary Journal | Relationship between Natriuretic Peptide Levels with Heart and Kidney Parameters in Rats with Chronic Renal Failure. [] |
| Acta Pharmaceutica Sinica B | The poly (ADP-ribosyl) ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy [34094834] |
| Peptides | Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy [34624429] |
| Peptides | Osteocrin alleviates cardiac hypertrophy via attenuating oxidative stress [Pubmed:35218795] |
